Hydroxychloroquine reduces time to clinical recovery when treating COVID-19 disease patients:
The accelerating debate about the clinical benefit of treating COVID-19 disease patients with hydroxychloroquine became a little bit clearer with a new study.
Previous studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro.
As a derivative of CQ, hydroxychloroquine (HCQ) is reported to offer similar therapeutic effects, but with fewer adverse effects.
However, the scientific evidence regarding this antimalarial drug efficacy in COVID-19 patients is limited, since it is a new disease.
A new, small, non-peer-reviewed clinical study published on March 31, 2020, evaluated the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19 in China.
From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to the Renmin Hospital of Wuhan University, located in China.
All participants were randomized in a parallel-group trial #ChiCTR2000029559, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ.